[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"localized-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:localized-breast-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100414753","phase-2-per-operative-radiotherapy-by-papillon-tm-in-localized-breast-cancer-100414753",false,"NCT04680715","Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer","Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study","RPOS+2","Inclusion Criteria:\n\n* Patient with invasive ductal adenocarcinoma \\\u003C=2cm, evaluate on all radiological exams;\n* Women aged 65 years or older (patients 65 years of age in the year may be included);\n* Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2 status;\n* T0 or T1, N0 radio-clinic;\n* Operable patient with breast volume compatible with conservative surgery;\n* Patient with prior malignancy or other concurrent malignancies are eligible, including bilateral breast cancer\n* Patients who have been made aware of the information sheet and have given their written signed informed consent;\n* Patients benefitting from social health insurance coverage\n\nExclusion Criteria:\n\n* Age less than 65 years (except if 65 years obtained during the year)\n* Patient with an exclusive in situ carcinoma\n* Patient with lymphatic invasion \u002F peri-nerve involvement \u002F vascular emboli\n* Patient with a lobular adenocarcinoma\n* Patient with metastatic disease\n* Multifocal tumor\n* Patient with grade 3 or N+ disease\n* N1 proved by ultrasound guided\n* patient unable to express her consent\n* Patient deprived placed under the authority of a tutor\n* Female patients who are pregnant or breastfeeding\n* Vulnerable patient: as defined in article L1121-5 à -8","FEMALE","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.",[27],"Localized Breast Cancer","RECRUITING","2026-01-28",{"date":31,"type":32},"2026-01-29","ACTUAL",{"date":34,"type":32},"2021-07-16",{"date":36,"type":21},"2028-06",{"name":38,"class":39},"Centre Antoine Lacassagne","OTHER",2]